Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Mattila KE, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Mäkelä S, Hernberg M. Mattila KE, et al. Acta Oncol. 2020 Mar;59(3):310-314. doi: 10.1080/0284186X.2019.1670862. Epub 2019 Sep 28. Acta Oncol. 2020. PMID: 31564175 No abstract available.
Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
Tulokas SKA, Kohtamäki LM, Mäkelä SP, Juteau S, Albäck A, Vikatmaa PJ, Mattila KE, Skyttä TK, Koivunen JP, Tyynelä-Korhonen K, Hernberg MM. Tulokas SKA, et al. Among authors: mattila ke. Melanoma Res. 2021 Oct 1;31(5):456-463. doi: 10.1097/CMR.0000000000000755. Melanoma Res. 2021. PMID: 34132224
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE, Mäkelä S, Kytölä S, Andersson E, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Aittomäki K, Hernberg M. Mattila KE, et al. Acta Oncol. 2022 Oct;61(10):1263-1267. doi: 10.1080/0284186X.2022.2137693. Epub 2022 Oct 28. Acta Oncol. 2022. PMID: 36307938 Clinical Trial.
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
Vihinen H, Jokinen A, Laajala TD, Wahid N, Peltola L, Kettunen T, Rönkä A, Tiainen L, Skyttä T, Kohtamäki L, Tulokas S, Karhapää H, Hernberg M, Silvoniemi M, Mattila KE. Vihinen H, et al. Among authors: mattila ke. Clin Lung Cancer. 2023 Jun;24(4):295-304. doi: 10.1016/j.cllc.2023.01.004. Epub 2023 Jan 24. Clin Lung Cancer. 2023. PMID: 36774235 Free article.
41 results